Compare BioNano Genomics Inc (BNGO) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Wendys Co — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Wendys Co trades at $7.45 (market cap $1.41B). The key difference: Wendys Co is far larger — about 106.8× BioNano Genomics Inc's market cap, and Wendys Co pays a 7.55% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | WEN | |
|---|---|---|
Market Cap | $13.20M | $1.41B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $11.33 |
52-Week Low | $1.09 | $6.17 |
Enterprise Value | $15.81M | $5.23B |
Dividend Yield | — | 7.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Wendy's (WEN) trades at $7.50, down 0.66% on the day, with a bullish technical signal and recent meme-driven momentum. The stock shows strong valuation metrics with a P/E of 9.74 and P/S of 0.65, but faces declining net income margins, falling to 7.58% in 2025. Recent earnings beats and a 7.1% dividend yield attract income investors, while Project Fresh initiatives aim to counter traffic and cost pressures.
Outlook remains mixed: low valuation and retail enthusiasm offer upside, but margin compression and high debt pose risks. Analyst consensus is cautious with a $7.96 price target, suggesting limited near-term growth. Key catalysts include Q2 2026 results on August 7 and international expansion progress, though competitive and inflationary headwinds persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
